Amycretin Calculator
What is Amycretin?
Amycretin is a unimolecular GLP-1 / amylin co-agonist in early clinical development by Novo Nordisk. Unlike semaglutide, retatrutide, or tirzepatide, the molecule engages the amylin receptor in addition to GLP-1 — a dual-agonist mechanism more typically achieved through co-formulation, as in cagrilintide plus semaglutide ("CagriSema"). Both oral and subcutaneous formulations are under investigation. Phase 1b/2a data presented at the 2024 American Diabetes Association Scientific Sessions reported a mean weight reduction of approximately 24% over 36 weeks at the highest tested subcutaneous dose, the largest single-molecule effect reported to date in early-phase obesity trials. As of 2026 amycretin remains investigational; no commercial supply or research-grade material is established outside Novo Nordisk's trials.
| 3 mg | lyophilized powder |
| 6 mg | lyophilized powder |
| 0.5 mg | ≈ 16.7 U-100 units (at 6mg / 2mL) |
| 1 mg | ≈ 33.3 U-100 units (at 6mg / 2mL) |
| 2 mg | ≈ 66.7 U-100 units (at 6mg / 2mL) |
| 3 mg | ≈ 100 U-100 units (at 6mg / 2mL) |
| 6 mg | ≈ 200 U-100 units (at 6mg / 2mL) |
How it's typically prepared
Amycretin is investigational and not commercially available outside of Novo Nordisk's clinical trials, so any reconstitution figures shown here are illustrative only. If material were to become available to qualified researchers, the lyophilized powder would follow the GLP-1 class handling profile — reconstitution with bacteriostatic water, refrigerated storage at 2–8 °C, and use within 28 days of reconstitution.
Frequently asked questions
- Is amycretin available?
- Amycretin is investigational as of 2026 and is enrolled in Phase 2 / Phase 3 trials for obesity. It is not commercially supplied through any route — pharmacy, research, or otherwise.
- How does amycretin differ from semaglutide or retatrutide?
- Amycretin is a unimolecular GLP-1 / amylin co-agonist. Semaglutide is a GLP-1 mono-agonist; retatrutide is a triple agonist (GLP-1 / GIP / glucagon). Tirzepatide is a dual GLP-1 / GIP agonist. Amycretin's amylin component is mechanistically closer to cagrilintide and to native pancreatic amylin than to any of the incretin-class compounds.
- What efficacy has been published?
- Phase 1b/2a data showed approximately 24% mean weight loss over 36 weeks at the highest subcutaneous dose tested. Phase 3 outcomes are not yet published.
- Is amycretin oral or injectable?
- Both formulations are in development. Novo Nordisk has reported readouts on each.
- When is amycretin expected to receive regulatory approval?
- Novo Nordisk has not published a definitive submission timeline. Phase 3 readouts are the gating event; commercial availability would not be expected before late 2027 at the earliest.
- Is amycretin available as a research peptide?
- No. Amycretin is not produced by research peptide vendors and is restricted to clinical trial settings.
Other GLP-1 peptides
PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.